ATE314480T1 - Fusionsproteine aus hirudin und proinsulin oder insulin - Google Patents

Fusionsproteine aus hirudin und proinsulin oder insulin

Info

Publication number: ATE314480T1
Authority: AT; Austria
Prior art keywords: proinsulin; hirudin; insulin; fusion proteins; protein
Prior art date: 2001-02-20

Application number

AT02711847T

Other languages

English (en)

Inventor

Paul Habermann

Johann Ertl

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-20

Filing date

2002-02-08

Publication date

2006-01-15

2002-02-08 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2006-01-15 Application granted granted Critical

2006-01-15 Publication of ATE314480T1 publication Critical patent/ATE314480T1/de

Links

102000037865 fusion proteins Human genes 0.000 title abstract 3
108020001507 fusion proteins Proteins 0.000 title abstract 3
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000007625 Hirudins Human genes 0.000 title 1
108010007267 Hirudins Proteins 0.000 title 1
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
108010076181 Proinsulin Proteins 0.000 title 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title 1
229940006607 hirudin Drugs 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
102000004169 proteins and genes Human genes 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
230000001580 bacterial effect Effects 0.000 abstract 1
230000004927 fusion Effects 0.000 abstract 1
239000006228 supernatant Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Diabetes (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Obesity (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02711847T 2001-02-20 2002-02-08 Fusionsproteine aus hirudin und proinsulin oder insulin ATE314480T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10108212A DE10108212A1 (de)	2001-02-20	2001-02-20	Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
PCT/EP2002/001307 WO2002068660A1 (en)	2001-02-20	2002-02-08	Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Publications (1)

Publication Number	Publication Date
ATE314480T1 true ATE314480T1 (de)	2006-01-15

Family

ID=7674913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02711847T ATE314480T1 (de)	2001-02-20	2002-02-08	Fusionsproteine aus hirudin und proinsulin oder insulin

Country Status (18)

Country	Link
EP (1)	EP1364029B1 (de)
JP (1)	JP4243104B2 (de)
KR (1)	KR100858009B1 (de)
CN (1)	CN100500853C (de)
AT (1)	ATE314480T1 (de)
AU (1)	AU2002231784B2 (de)
BR (1)	BRPI0207394B8 (de)
CA (1)	CA2438886C (de)
DE (2)	DE10108212A1 (de)
DK (1)	DK1364029T3 (de)
ES (1)	ES2254658T3 (de)
IL (1)	IL157414A0 (de)
MX (1)	MXPA03007114A (de)
NO (1)	NO331271B1 (de)
NZ (1)	NZ527643A (de)
PE (1)	PE20020876A1 (de)
WO (1)	WO2002068660A1 (de)
ZA (1)	ZA200305869B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9453251B2 (en)	2002-10-08	2016-09-27	Pfenex Inc.	Expression of mammalian proteins in Pseudomonas fluorescens
CA2546157C (en)	2003-11-21	2014-07-22	Dow Global Technolgies Inc.	Improved expression systems with sec-system secretion
EP1709170B1 (de)	2004-01-16	2018-02-21	Pfenex Inc.	Expression von säugerproteinen in pseudomonas fluorescens
BRPI0513826A2 (pt)	2004-07-26	2010-06-22	Dow Global Technologies Inc	processo para expressão de proteìna melhorada através de engenharia de cepa
DE102006031962A1 (de)	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidiertes Insulin Glargin
DE102006031955A1 (de) *	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006050332A1 (de)	2006-10-25	2008-04-30	Wacker Chemie Ag	DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
EP2468869B1 (de)	2007-01-31	2015-03-18	Pfenex Inc.	Bakterielle Leader-Sequenzen für erhöhte Expression
US9394571B2 (en)	2007-04-27	2016-07-19	Pfenex Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en)	2007-04-27	2017-02-28	Pfenex, Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
DE102008025008A1 (de)	2008-05-24	2009-11-26	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de)	2008-05-24	2009-11-26	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MY152979A (en)	2008-01-09	2014-12-15	Sanofi Aventis Deutschland	Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
JP5695909B2 (ja)	2008-01-09	2015-04-08	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
WO2010038145A2 (en) *	2008-10-02	2010-04-08	Unitargeting Research As	Kit for the optimisation of protein synthesis/secretion
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
PL2968470T3 (pl)	2013-03-12	2021-05-31	The General Hospital Corporation	Zmodyfikowane białka stanowiące substancję hamującą rozwój przewodów müllera (mis) i ich zastosowania do leczenia chorób
ES2912283T3 (es)	2013-12-11	2022-05-25	Massachusetts Gen Hospital	Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1341417C (fr) *	1984-03-27	2003-01-21	Paul Tolstoshev	Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
GB8927722D0 (en) *	1989-12-07	1990-02-07	British Bio Technology	Proteins and nucleic acids
ES2093717T3 (es) *	1990-11-08	1997-01-01	Japan Energy Corp	Mutante de hirudina, su produccion, anticoagulante, vector secretor, microorganismo transformado por el indicado vector y produccion de un producto a partir de dicho microorganismo.
WO1995009125A1 (en) *	1992-09-28	1995-04-06	Pehr Harold T	Kicker latch for container closures
DE10033195A1 (de) *	2000-07-07	2002-03-21	Aventis Pharma Gmbh	Bifunktionale Fusionsproteine aus Hirudin und TAP

2001
- 2001-02-20 DE DE10108212A patent/DE10108212A1/de not_active Withdrawn
2002
- 2002-02-06 PE PE2002000081A patent/PE20020876A1/es not_active Application Discontinuation
- 2002-02-08 KR KR1020037010943A patent/KR100858009B1/ko not_active Expired - Lifetime
- 2002-02-08 NZ NZ527643A patent/NZ527643A/en not_active IP Right Cessation
- 2002-02-08 IL IL15741402A patent/IL157414A0/xx active IP Right Grant
- 2002-02-08 DK DK02711847T patent/DK1364029T3/da active
- 2002-02-08 AT AT02711847T patent/ATE314480T1/de active
- 2002-02-08 MX MXPA03007114A patent/MXPA03007114A/es active IP Right Grant
- 2002-02-08 DE DE60208343T patent/DE60208343T2/de not_active Expired - Lifetime
- 2002-02-08 EP EP02711847A patent/EP1364029B1/de not_active Expired - Lifetime
- 2002-02-08 CA CA2438886A patent/CA2438886C/en not_active Expired - Lifetime
- 2002-02-08 WO PCT/EP2002/001307 patent/WO2002068660A1/en not_active Ceased
- 2002-02-08 CN CNB028068505A patent/CN100500853C/zh not_active Expired - Lifetime
- 2002-02-08 BR BRPI0207394A patent/BRPI0207394B8/pt not_active IP Right Cessation
- 2002-02-08 JP JP2002568754A patent/JP4243104B2/ja not_active Expired - Lifetime
- 2002-02-08 AU AU2002231784A patent/AU2002231784B2/en not_active Expired
- 2002-02-08 ES ES02711847T patent/ES2254658T3/es not_active Expired - Lifetime
2003
- 2003-07-30 ZA ZA200305869A patent/ZA200305869B/en unknown
- 2003-08-19 NO NO20033673A patent/NO331271B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR100858009B1 (ko)	2008-09-11
WO2002068660A1 (en)	2002-09-06
BRPI0207394B8 (pt)	2021-05-25
BRPI0207394B1 (pt)	2015-06-16
CA2438886A1 (en)	2002-09-06
DE60208343T2 (de)	2006-06-22
EP1364029A1 (de)	2003-11-26
NO331271B1 (no)	2011-11-14
MXPA03007114A (es)	2003-11-18
DK1364029T3 (da)	2006-05-08
KR20030074842A (ko)	2003-09-19
NO20033673L (no)	2003-10-17
HK1065335A1 (zh)	2005-02-18
ES2254658T3 (es)	2006-06-16
DE10108212A1 (de)	2002-08-22
CN1529757A (zh)	2004-09-15
AU2002231784B2 (en)	2006-10-26
CN100500853C (zh)	2009-06-17
BR0207394A (pt)	2004-02-10
IL157414A0 (en)	2004-03-28
NO20033673D0 (no)	2003-08-19
JP2004518444A (ja)	2004-06-24
ZA200305869B (en)	2004-06-25
CA2438886C (en)	2013-07-23
EP1364029B1 (de)	2005-12-28
JP4243104B2 (ja)	2009-03-25
NZ527643A (en)	2005-07-29
PE20020876A1 (es)	2002-11-05
DE60208343D1 (de)	2006-02-02

Legal Events

Date

Code

Title

Description

2007-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1364029

Country of ref document: EP

2007-07-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
ATE314480T1 (de)	2006-01-15	Fusionsproteine aus hirudin und proinsulin oder insulin
HUS1500024I1 (hu)	2017-04-28	GLP-1 analóg fúziós proteinek
WO2005021592A3 (en)	2005-06-09	Enhancing the circulating half-life of interleukin-2 proteins
PL1699822T3 (pl)	2008-08-29	Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
EP1534834A4 (de)	2006-05-24	Denaturierungsmittel-stabile und/oder proteaseresistente chaperon-ähnliche oligomere proteine, diese codierende polynukleotide, ihre verwendungen sowie verfahren zur erhohung einer spezifischen aktivitat davon
DE69435307D1 (de)	2010-09-16	Bazillus Thuringiensis und dessen insektizide Proteine
AU2002214542A1 (en)	2002-04-08	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2006097708A3 (en)	2007-01-25	Affinity purification of protein
AU2002258630A1 (en)	2002-10-15	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2001288363A1 (en)	2002-03-04	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
ATE412753T1 (de)	2008-11-15	Antibakterielles protein chlamysin-b, dafür kodierendes gen und ein expresionssystem dafür
AU2003287108A1 (en)	2004-06-23	Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production
AU2002229060A1 (en)	2002-07-01	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
EP1395674A4 (de)	2005-04-20	Isolierte menschliche proteaseproteine, menschliche proteaseproteine codierende nukleinsäuremoleküle und verwendungen davon
EP1379678A4 (de)	2005-04-13	Isolierte menschliche proteaseproteine, menschliche proteaseproteine codierende nukleinsäuremoleküle und verwendungen davon
AU2002232452A1 (en)	2002-06-18	Human transporter proteins, nucleic acid molecules encoding them,and uses thereof
AU2001253804A1 (en)	2001-11-07	Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
AU2002245128A1 (en)	2002-07-30	Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
EP1419251A4 (de)	2005-05-04	Isolierte menschliche transporterproteine, menschliche transporterproteine codierende nukleinsäuremoleküle sowie verwendungen davon
IL204767A (en)	2015-07-30	Stable chimeric oligomeric proteins for denture and protease resistant
AU2002228599A1 (en)	2002-06-03	Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof
EP1472274A4 (de)	2005-12-28	Isolierte humane transporterproteine, nukleinsäuremoleküle, die für humane transporterproteine codieren, und deren verwendung
EP1384077A4 (de)	2005-06-15	Isolierte menschliche transporterproteine, menschliche transporterproteine codierende nukleinsäuremoleküle sowie verwendungen davon
AU2002243460A1 (en)	2002-07-16	Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
AU2002307004A1 (en)	2002-10-15	Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof